



New Drug Therapy for Substance Disorders: GLP-1R Agonists

Lunde Dadiane A*, Lunde Dadon JDV, Bridgesson S, Deaths S and Trondheim S

Sobibor Toxicology Institute, Himmler Institute of Arctic Industrial Business and Engineering, Research Institute Allied Health, Rural Research Center of Arctic, Department of Osteopathic Robotics Surgery, Clinical Research Board of Governing Didactic Research Series, Outlying Islands

*Corresponding author: Lunde Dadiane A, Sobibor Toxicology Institute, Himmler Institute of Arctic Industrial Business and Engineering, Research Institute Allied Health, Rural Research Center of Arctic, Department of Osteopathic Robotics Surgery, Clinical Research Board of Governing Didactic Research Series, Outlying Islands; E-mail: mllcsage808@gmail.com

Abstract

In this Research Article we explain the Medical Dossier information collected through APC and Dossier Codification of diagnosis of substance abuse. Using this tool, we have a collective data set where we can treat and diagnose substance abuse disorders and addiction medicine protocols. Here we focus on underlying conditions affecting the prognosis of substance abuse and addiction medicine diagnostic criteria.

Keywords: Substance abuse; Chemical compounds; Diagnosis for underlying conditions; Opioid's; Heroin; Cocaine; Drug manufacturer; ATMP and Vector Control Products; Vaccines

Introduction

In this Research Article we explain the Medical Dossier information collected through APC and Dossier Codification of diagnosis of substance abuse. Using this tool, we have a collective data set where we can treat and diagnose substance abuse disorders and addiction medicine protocols. Here we focus on underlying conditions affecting the prognosis of substance abuse and addiction medicine diagnostic criteria. The GLP-1 functions show suppression in opioid abuse such as heroin, fentanyl, and morphine. It appears in studies and case reports that liraglutide reduced craving for opioids and RCT in individuals with OUD. GLP-1R agonist medication used for addiction treatment and substance abuse as an underlying condition. RCT (Randomized Controlled Trial) and Opioid Use Disorder is (OUD). The primary focus of RCT in Vector Control Products (vaccines) is to adhere to efficacy and safety in treatment interventions across the globe. Advanced Therapeutic Medicinal Products are tested through Pharmaceutical Trials for results in treating conditions and underlying pre-existing conditions, we will elaborate here. (Figure 1) [1].

Chemical Compound and Treatment Diagnosis

Chemical Compounding information and research is important for setting drugs under classification for Addiction Drug Treatment. Preparing a Diagnosis through Pharmacology and Drugs Chemical Compounding Data is a rationale method to release the drug into the environmental with supportive documentation. For GLP-1R agents we used the generic MeSH Name for Liraglutide is a lipopeptide that is an analogue of human GLP-1 in which the lysine residue at position 27 is replaced by arginine and a hexadecanoyl group attached to the remaining lysine via a glutamic acid spacer. Used as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. It has a role as a glucagon-like peptide-1 receptor agonist and a neuroprotective agent. It is a lipopeptide and a polypeptide. We distinguished the issue with Diabetes mellitus and the glycaemic control mechanisms to opioid, heroin, and cocaine drug abuse. The information will be retained in this study to show that controlling glycaemic index in a "body" assists in the Addiction Medicine diagnosis and treatment (Figure 2).

Received date: 10 Septmeber 2025; Accepted date: 20 October 2025; Published date: 31 October 2025

Citation: Lunde Dadiane A, Lunde Dadon JDV, Bridgesson S, Deaths S, Trondheim S (2025) New Drug Therapy for Substance Disorders: GLP-1R Agonists. SunText Rev Case Rep Image 6(4): 165.

DOI: <https://doi.org/10.51737/2766-4589.2025.165>

Copyright: © 2025 Lunde Dadiane A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Figure 1: Addiction Medicine track outcomes of variety of Drug Abuse rituals, tools, and how affect one another.




Figure 2: GLP-1R is research studied chemical drug used in pharmaceuticals for Randomized Controlled Trials and for OUD (Opioid Used Disorder). (IUPHAR, 2012).

Here we index the trial data for the FDA approved Drug Classification:

In order:

- WIPO PATENTSCOPE
Patents are available for this chemical structure:
Cas No. 204656-20-02 Molecular Weight 3200 g/mol
<https://patentscope.wipo.int/search/en/result.jsf?inchikey=YS DQQAXHVYUZIW-QCIJIYAXSA-N>
- FDA Orange Book Patents
1 US Patent Trade AIPLA Name: Liraglutide Application Number: (ECHA) 810-818-7per g/Mol= 3200-3800 g/mol 9968659*PED
SAXENDA
206321
- PubChem CID
16134956
Structure and Bioassay Data

- IUPAC Condensed
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(1)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH. Palmitoyl-Glu(1)-OH
- Chemical Safety Sheets
Laboratory Chemical Safety Summary (LCSS) Datasheet
Molecular Formula
 $C_{172}H_{265}N_{43}O_{51}$

Chemical Compound and Treatment Diagnosis

The importance in providing the GLP-1R (EX 4 Liraglutide) to patients with substance abuse is the perform a case study that provides a taxonomy of chemical safety data sheets, and treatment diagnosis. Although after reviewing the chemical compound affects, we declare the treatment for the glycemic index was the first set of medication trial, to reduce the manifestations of diabetes, and cravings. Once we controlled the cravings, and diabetes with the GLP-1R Chemical Depository and Effect Data, the treatment diagnosis, was properly aligned with a substance abuse case, and underlying condition of diabetes or glycemic disorders. The glucose disorder causes the cravings and creates a self-medicating ritual for controlling "body" signals or receptors. This all explain during the RCT, the chemical compounding, and the Medications Usage declaration or disclaimer [2] (Figure 2).

Methodology of Applied Science to Substance Abuse

Some methods we use for GLP-1R (EX 4 Liraglutide), was to take a Blood Sample, and we continued with the Toxicology Tests, and further assigned the participants to a Addiction Medicine specialists, and substance abuse center. (PubMed, Chem Sci} After collecting pathology reports over time, we decided to perform a RCT for OUD participants, the participants were provided with a full report and all had a underlying condition of glucose disorder, and hepatic disorders. We provided the organic form of GLP-1R (EX-4 Liraglutide) over a course of 14 days, the cravings were reduced significantly and remarkably the Toxicology and Pathology Reports from Quest Laboratory Blood Bank provided us a Statistical Reports of the reduction of opioids, heroin, cocaine, alcohol, no fentanyl, and marijuana (THC) [1].

Summary and Conclusions

In providing a brief outlook on the GLP-1R, we tracked outcomes by Blood Tests, we adhered to chemical compounding standards (essential medication safety). We controlled the group through a set of Addiction Medicine, and Substance Abuse Compliance Forms. And we set our standards for further study into Chemicals and reactions of substance abuse with medications. Our overview overlooked one issues, which was the issue of blood tests, and type of substance that was used in abusive methods. Our research

and our case study summarized that the classification of GLP-1R was properly assigned for treating underlying conditions. Any drug with high levels of H⁺ or C⁺ were documented for our next series and Laboratory Biopharmaceuticals Studies. The research covers the GLP-R1 (EX Liraglutide), Chemical Compound information, the diagnosis and prognosis, the Applied Metrics to substance abuse, and Randomized Trials for Opioid Use and Abuse. The research continues on a more in-depth study for Randomized Trials and Substance Abuse by Addiction Medicine Professionals [3-5] (Figure 3).



Figure 3: Participants are randomly assigned to different treatment groups, iconically the groups are similar at the start of the study. {EPA, 2011} {Toxic Pharmacol}.

Acknowledgment

We are a Patent Company that has a Research Department and we are a Private Publishing Firm.

References

1. Keene L. Sports medicine case reports: addictions to excessive exercise. Architects of addictive behavior. Article 1. DSC-Patent. Keene Med J Online Pub. Psych Chem. 2010; 1-99.
2. ECHA- Chemical substance and digital publishing. NIDA Cross Ref. For easy access to drugs online. PMID. PMC. Grants and scholarships. Chem Pharmacol. 2009
3. IUPHAR. Emerging Pharmacotherapeutic agent. Conferences IUPHARM. Article 1. Lynne Keene Pharm-D Pharmacol. 2016; 2.
4. PubChem. Liraglutide-API manufacturer. Chemical compound safety and risks. Chem Sci. 2010. Premier MD 2009.
5. EPA. CompTOX access chemical dashboard. Liraglutide. Executive summary CompTIA. 2011. Toxic Pharmacol.